Celyad Oncology Operating Income

Celyad Oncology (CYAD) currently reports a operating income of $-16M as of December 2024. That compares with $-10K in the prior-year period — down 163840.0% year over year. Use the charts on this page to explore Celyad Oncology's operating income history and peer comparisons.

Celyad Oncology's operating income decreased from $-10K to $-16M — a 163840.0% year-over-year decrease (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Celyad Oncology reported $-16M in operating income as of December 2024. That compares with $-10K in the prior-year period — down 163840.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-16M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Celyad Oncology, and consider following CYAD for alerts when major investors trade the stock.

Celyad Oncology is classified in the Healthcare sector. On operating income, it currently shows $-16M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYAD with unrelated industries.